BioCentury | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

...to express TCRs against a given target. ADP-A2AFP targets AFP; ADP-A2M4 targets MAGEA4; ADP-A2M10 targets MAGEA10...
...expresses the CD8α co-receptor. Targets - AFP - Alpha fetoprotein; MAGEA4 - Melanoma-associated antigen 4; MAGEA10...
BioCentury | Aug 22, 2019
Emerging Company Profile

Tscan: Tracking down novel T cell targets

...Other companies developing TCR therapies include Adaptimmune, which has three programs against known TCR targets MAGEA10...
...TTN - Titin MAGEA3 - Melanoma-associated antigen A3 MAGEA4 - Melanoma-associated antigen A4 MAGEA10 - Melanoma-associated antigen A10 Elizabeth...
BioCentury | Aug 2, 2019
Clinical News

Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

...tyrosine kinase; CD73 (NTSE) - Ecto-5’-nucleotidase Sandi Wong, Staff Writer MAGE A10 TCR, MAGE-A10 SPEAR T-cell therapy (MAGEA10...
...MAGEA4 TCR Masiviera, masitinib (AB1010, masican, masipro) TJD5 AB Science S.A. Adaptimmune Therapeutics plc I-Mab Biopharma Kiyatec Inc. NIH Tracon Pharmaceuticals Inc. Ecto-5'-nucleotidase (CD73) (NT5E) Melanoma-associated antigen A10 (MAGEA10) Melanoma-associated...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...Ph I MAGEA4 Adaptimmune Therapeutics plc (NASDAQ:ADAP) MAGE-A4 SPEAR T-cell therapy Solid tumors Ph I Melanoma-associated antigen A10 (MAGEA10)...
BioCentury | Oct 26, 2018
Clinical News

Adaptimmune reports zero responses across three T cell therapy trials

...one with treatment-related CRS and encephalopathy. MAGE-A10 comprises T cells modified to express TCRs targeting melanoma-associated antigen A10 (MAGEA10)...
...therapy Business: Cancer Molecular target: Melanoma-associated antigen A10 (MAGEA10); MAGEA4 Description: T cells modified to express TCRs targeting MAGEA10...
...MAGE-A10 SPEAR T-cell therapy (MAGEA10 TCR) MAGE A4 TCR, MAGE-A4 SPEAR T-cell therapy, MAGEA4 TCR Adaptimmune Therapeutics plc Melanoma-associated antigen A10 (MAGEA10) Melanoma-associated...
BioCentury | Oct 22, 2018
Clinical News

Adaptimmune reports zero responses across three T cell therapy trials

...one with treatment-related CRS and encephalopathy. MAGE-A10 comprises T cells modified to express TCRs targeting melanoma-associated antigen A10 (MAGEA10)...
...MAGE-A10 SPEAR T-cell therapy (MAGEA10 TCR) MAGE A4 TCR, MAGE-A4 SPEAR T-cell therapy, MAGEA4 TCR Adaptimmune Therapeutics plc Melanoma-associated antigen A10 (MAGEA10) Melanoma-associated...
BioCentury | Jun 8, 2018
Clinical News

Adaptimmune reports Phase I safety data for TCR therapy

...Oncology (ASCO) meeting in Chicago. The therapy comprises T cells modified to express TCRs targeting melanoma-associated antigen A10 (MAGEA10)...
...cell therapy Business: Cancer Molecular target: Melanoma-associated antigen A10 (MAGEA10) Description: T cells modified to express TCRs targeting MAGEA10...
...2018) Allison Johnson MAGE A10 TCR, MAGE-A10 SPEAR T-cell therapy (MAGEA10 TCR) Adaptimmune Therapeutics plc American Society of Clinical Oncology ASCO Melanoma-associated antigen A10 (MAGEA10)...
BioCentury | Sep 8, 2017
Company News

GSK nabs Adaptimmune’s NY-ESO SPEAR T cell therapy program

...Following the exercise, Adaptimmune’s pipeline comprises T cell therapies against melanoma-associated antigen A4 (MAGEA4) and MAGEA10...
...James Noble told BioCentury that cancer/testis antigens, which include the biotech's NY-ESO, PRAME, MAGEA4 and MAGEA10...
BioCentury | Sep 8, 2017
Company News

GSK exercises option for Adaptimmune’s NY-ESO SPEAR T cell therapy program

...Following the exercise, Adaptimmune’s pipeline comprises T cell therapies against melanoma-associated antigen A4 (MAGEA4) and MAGEA10...
BioCentury | Jul 20, 2017
Product R&D

Eureka moment for TCR mimics

...eight companies have engineered TCRs that recognize specific intracellular tumor antigen-MHCI complexes, including PRAME, WT1, MAGEA10...
...believes its CAR T cells benefit from easier CMC and better clinical validation. MAGEA10 - Melanoma-associated antigen A10...
...Melanoma-associated antigen A3 MAGEA4 - Melanoma-associated antigen A4 MAGEA6 - Melanoma-associated antigen A6 MAGEA10 - Melanoma-associated antigen A10...
Items per page:
1 - 10 of 13